nav-left cat-right
cat-right

New screening strategy introduced to develop possi...

Scientists have developed a new drug-discovery strategy, which will help them in rapidly selecting chemical compounds that will have a desired effect on cells. Researchers from the Scripps Research Institute (TSRI) has also tried to highlight how these compounds will work. Scientists have identified a compound that shows promise for treating obesity-linked diabetes by using the innovative technique, and were able to identify...

Immunocore and GlaxoSmithKline team to work on imm...

Immunocore’s list of collaborators is beginning to look like a Who’s Who in Big Pharma. Today the biotech–which is developing T cell immunotherapy technology originally spun out of Oxford–added a deal-hungry AstraZeneca ($AZN) and its biologics team at MedImmune as its latest partner, which will now join Genentech and GlaxoSmithKline in exploring whether the biotech has really found a powerful new...

Ancient mystery of cell division solved

An international team of scientists led by the University of Göttingen has deciphered a key mechanism of cell division. A striking feature of cell division is the condensation or compaction of chromosomes, which was first observed more than 130 years ago, but whose mechanism had been only vaguely understood so far. The Göttingen researchers successfully identified a force in a dividing cell that drives this process. The...

Epigenetics enigma resolved

Scientists have obtained the first detailed molecular structure of a member of the Tet family of enzymes. The finding is important for the field of epigenetics because Tet enzymes chemically modify DNA, changing signposts that tell the cell’s machinery “this gene is shut off” into other signs that say “ready for a change.” Tet enzymes’ roles have come to light only in the last five years;...

Billionaire backs new program for a pioneering Alz...

German billionaire Dietmar Hopp is adding to his multimillion-dollar wager on AC Immune, the Swiss biotech that is playing a key role in some high-profile Alzheimer’s programs. Hopp has been the primary investor behind the company, and today he joined in a $22 million D round designed to fund a new therapeutic vaccine program aimed at the memory-wasting disease. AC Immune isn’t built like most biotechs. CEO Andrea...

Cancer Research UK will repurpose an AstraZeneca a...

Cancer Research UK has struck a deal with AstraZeneca ($AZN) to repurpose an experimental therapy originally developed by the drug giant for asthma and study its ability to fight kidney cancer. Under the agreement, the nonprofit’s drug development office will carry out preclinical testing and early clinical trials of the compound, AZD2098. Cancer Research UK plans to begin enrolling up to 40 patients in an early phase...
Page 30 of 153« First...1020...2829303132...405060...Last »